Agenus Inc's Cash & cash equivalent grew by 363.96 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Agenus Inc's Quick Ratio to 0.43, Quick Ratio remained below Agenus Inc average.

Within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Agenus Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 3314 to 3889.

Explain Quick Ratio?
How much Cash & cash equivalents AGEN�s has?
What are AGEN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AGEN/financial-strength

https://api.csimarket.com/api/v1/companies/AGEN/fundamentals

https://api.csimarket.com/api/v1/companies/AGEN/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

AGEN Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-29.06 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	2414.05 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.43	Subscribe	Subscribe	Subscribe	Subscribe
AGEN's Total Ranking	# 3889	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-12.13 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	363.96 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 142
Healthcare Sector	# 866
Overall Market	# 3889

Quick Ratio Statistics
High	Average	Low
7.04	2.06	0.01
(Sep 30 2015)		(Dec 31 2025)

Financial Statements
Agenus Inc's Current Liabilities	$ 204 Millions	Visit AGEN's Balance sheet
Agenus Inc's Cash & cash equivalent	$ 87 Millions	Visit AGEN's Balance sheet
Source of AGEN's Sales		Visit AGEN's Sales by Geography

Cumulative Agenus Inc's Quick Ratio

AGEN's Quick Ratio for the trailling 12 Months

AGEN Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	5.97 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	99.77 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.14	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4117	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-7.64 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	138.69 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to AGEN Financial Strength Comparisons >> Go to Compare AGEN Quick Ratio to its Competitors

On the trailing twelve months basis AGEN Cash & cash equivalent more than doubled by 2414.05 % in Q3 2026 year on year, while Current Liabilities fell to $204 millions, this led to increase in in Agenus Inc's Quick Ratio to 0.14, Quick Ratio remained below AGEN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 143 other companies have achieved higher Quick Ratio than Agenus Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3986 to 4117.

Explain Quick Ratio?
How much Cash & cash equivalents AGEN�s has?
What are AGEN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 144
Healthcare Sector	# 912
Within the Market	# 4117

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.07	1.84	0.03
(Dec 31 2015)		(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Metagenomi Therapeutics Inc	1.12	$ 36.107 Millions	$ 32.340 Millions
Amgen Inc	1.11	$ 25,811.000 Millions	$ 23,231.000 Millions
Coherus Oncology inc	1.11	$ 83.629 Millions	$ 75.636 Millions
Sab Biotherapeutics Inc	0.98	$ 14.438 Millions	$ 14.798 Millions
Passage Bio Inc	0.97	$ 20.160 Millions	$ 20.743 Millions
Bio techne Corp	0.97	$ 350.036 Millions	$ 361.269 Millions
C4 Therapeutics Inc	0.81	$ 33.492 Millions	$ 41.460 Millions
Allogene Therapeutics Inc	0.76	$ 29.270 Millions	$ 38.498 Millions
Protalix Biotherapeutics inc	0.73	$ 22.035 Millions	$ 30.233 Millions
Ocugen Inc	0.71	$ 84.257 Millions	$ 118.901 Millions
Neurocrine Biosciences Inc	0.59	$ 739.100 Millions	$ 1,242.800 Millions
Iovance Biotherapeutics inc	0.55	$ 57.934 Millions	$ 105.774 Millions
Agenus Inc	0.43	$ 86.936 Millions	$ 203.691 Millions
Vaxcyte Inc	0.42	$ 125.470 Millions	$ 295.697 Millions
Vaxart Inc	0.41	$ 30.435 Millions	$ 73.934 Millions
Surrozen Inc	0.35	$ 100.353 Millions	$ 286.684 Millions
Biogen Inc	0.16	$ 628.100 Millions	$ 3,898.400 Millions

Date modified: 2026-11-07T13:17:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.